System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Vladimir Koblizek is an expert in Pulmonology at University Hospital Hradec Králové (Czechia). As of October 2026, ScienceLeadR ranks Vladimir Koblizek in the top 1% of experts in Czechia for Lung Diseases, Obstructive. Vladimir Koblizek has authored 133 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 4 of them ongoing. SLR score: 507 (community average: 125). How the SLR is computed.

LeadR Profile

Vladimir Koblizek University Hospital Hradec Králové Czechia
507 ScienceLeadR Reputation 507

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Public Health - Oncology - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026
Source: PubMed

University Hospital Hradec Králové

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 133

Citations

Citations: 1 337 1st author: 33 Last author: 31 Unique author: 2

Main journals

05.02 - Monitoring airway disease 20
Vnitr Lek 13
Int J Chron Obstruct Pulmon Dis 8
09.02 - Physiotherapists 7
05.01 - Airway pharmacology and treatment 5

Best Journals

Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Expiratory time constant patterns reveal obstructive lung mechanics in non-obstructive spirometry.
PMID 42579716 — mechanics, lung, spirometry, vital capacity		PLOS Digit Health20260
Aerodynamic barriers to inhaled furosemide delivery during dyspnoea revealed by experimental and computational modelling.
PMID 42260075 — air, natural science disciplines, furosemide		Sci Rep20260
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
PMID 42150581 — safety, blood, eosinophils, drug-related side effects and adverse reactions, pulmonary disease, chronic obstructive, therapeutics, interleukin-33, history		Lancet Top journal20261
Pulmonary Dynamics of the Bronchodilator Response in Volume-Responsive Asthma and COPD.
PMID 41903838 — bronchodilator agents, spirometry, pulmonary disease, chronic obstructive, asthma		Chest20260
Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data.
PMID 41605572 — lung, neoplasms, drug therapy, lung neoplasms, therapeutics		BMJ Open Respir Res20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 1

By phase:

N/A 5
Phase 2 1
Phase 2/Phase 3 1
Phase 3 1

By status:

Recruiting 5
Completed 2
Unknown 1

By type:

Interventional 4
Observational 4

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 1
multicentricup10 3

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Advanced Respiratory Diseases (INFURO)
2024-514672-41-00 — lung, perception, furosemide, lung diseases, dyspnea		Phase 2Recruiting2024
Adherence to Inhaled Therapy a Globally Overlooked Problem in Patients With Chronic Obstructive Pulmonary Disease and Bronchial Asthma
NCT07183657 — chronic disease, inhalation, pulmonary disease, chronic obstructive, mobile applications, therapeutics, asthma, lung diseases, education, lung diseases, obstructive, educational status		N/ARecruiting2025
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
NCT06252454 — respiration disorders, lung, respiratory tract diseases, respiration, sensation, furosemide, dyspnea		Phase 2/Phase 3Recruiting2024
Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID 19) Patients
NCT04887623 — pilot projects, coronavirus, pilots, serum, interleukin-6, viral load, respiratory tract infections, nucleocapsid, covid-19, viremia, communicable diseases, infections		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS